Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emory University School of Medicine

Division of Emory University
www.emory.edu/WHSC/MED

Latest From Emory University School of Medicine

Regeneron And Geisinger Get Ambitious In Next-Gen Genomics

Regeneron and Geisinger’s new collaboration to identify genetic variants and apply that knowledge to drug discovery and patient care is pharma’s most ambitious effort to date to exploit next-generation genomics, but its impact on drug discovery productivity won’t be known for years.

BioPharmaceutical Business Strategies

TAVR Emerging As Next Big Application For Embolic Protection Devices

Studies suggest transcatheter aortic valve replacement is associated with a higher stroke risk than standard surgical valve replacement, presumably due to embolic debris released during the TAVR procedure. To address this concern, several companies are developing TAVR-specific embolic protection devices, and their success may prove to be a key driver of future growth in this $1+ billion market.

Medical Device

Micro Interventional Devices: Creating A Tool Box For Structural Heart Disease

Micro Interventional Devices was founded around opportunities in addressing the procedural challenges that limit patient access to transcatheter heart valves. The company’s initial focus is on developing a transcatheter valve for the replacement of the mitral valve, and an easy and effective transapical access and closure method for transcatheter mitral and aortic valve procedures. The company’s mission, though, is to broadly focus on advancing structural heart disease treatments, and MID’s first-generation technology has potential application to several areas of structural heart disease, including PFO/atrial septal defect closure, left atrial appendage closure and cardiac ablations.

Medical Device

Genomics Through The Lens Of Precompetitive Data Sharing

With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.

Medical Device Strategy
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Tech. Transfer Entity
  • Parent & Subsidiaries
  • Emory University
  • Senior Management
  • Contact Info
  • Emory University School of Medicine
    Phone: (404) 727-5640
    1440 Clifton Road
    Atlanta, GA 30322
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register